Calidi Biotherapeutics (CLDI) Q4 2024 Annual Earnings
CLDI·Reported April 4, 2025·Before market open
Calidi Biotherapeutics reported Q4 2024 revenue of $1.5M. Diluted EPS came in at $-0.51, missed the $-0.37 consensus by $0.14.
Revenue
$1.5M
Diluted EPS
$-0.51missed by $0.14
Consensus: $-0.37
Financial Snapshot
Trailing eight quarters through Q4 2024
Q4 2024 Earnings FAQ
Common questions about Calidi Biotherapeutics's Q4 2024 earnings report.
Calidi Biotherapeutics (CLDI) reported Q4 2024 earnings on April 4, 2025 before market open.
Calidi Biotherapeutics reported revenue of $1.5M and diluted EPS of $-0.51 for Q4 2024.
EPS missed the consensus estimate of $-0.37 by $0.14.
You can read the 10-K periodic report (0001641172-25-001810) directly on SEC EDGAR. The filing index links above go to sec.gov.